Fibrinolytic (clot-dissolving) drugs

Fibrinolytic drugs, also called thrombolytics, are medicines that dissolve blood clots that have already formed. MedlinePlus says they may be given for large clots in the lung that cause severe symptoms or other serious complications, and that they can cause sudden bleeding, so they are used when the pulmonary embolism is serious and may be life-threatening. This is the class page: each medicine has its own page.

Also called Fibrinolytic agents · Thrombolytics · Thrombolytic drugs

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH heading D005343, Fibrinolytic Agents, is an exact match, with the scope note fibrinolysin or agents that convert plasminogen to fibrinolysin. The one product label read, for alteplase, says the medicine binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, which starts local fibrinolysis. The label lists acute ischemic stroke, acute myocardial infarction and acute massive pulmonary embolism as uses. The MedlinePlus statement concerns pulmonary embolism only. No trial result and no dose is recorded here.

Trials at a glance

The figures count the 32 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
32
Phase 3 or 4
26
Recruiting
16
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingCompletedTerminatedUnknown statusAll statuses
Phase 2202004
Phase 2/3200002
Phase 311532223
Phase 4101013
All phases16562332

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 17 more.

Drugs in this class

2 drugs in this atlas are filed under Fibrinolytic (clot-dissolving) drugs, with the registry trials and FDA regulatory decisions this atlas holds for each. With Fibrinolytic (clot-dissolving) drugs itself, the class has 65 distinct trials and 2 distinct FDA decisions; a trial or decision that two of them share counts once there.

About this drug

Level
Class
Mechanism
Convert plasminogen to plasmin, which breaks down fibrin in a clot (MeSH scope note; US drug label for alteplase).

Claims and evidence

No claims are published for this drug yet.

Registry records

Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry trials 32

Record details

Record id
cardio:fibrinolytic-clot-dissolving-drugs
Content hash
130ad03cec0f571148915156f114b4455b2026079cbca001c326969de2e8a672